Zinger Key Points
Qiagen sees Q1 sales up ~5% to $483M, topping prior outlook despite missing street consensus. QIAstat-Dx and QuantiFERON test drive growth; EPS raised to $2.35 amid early margin target achievement. With stocks plunging, steady income is key. Tim Melvin & Ryan Faloona reveal dividend stocks and deep-value plays on April 8. Reserve your spot now.Qiagen N.V. QGEN shares are trading higher premarket on Monday. On Sunday, the company disclosed its preliminary results for the first quarter of 2025 .
The company sees net sales growth of around 5% (+7% at constant exchange rates, CER) to about $483 million vs. consensus of $506.5 million.
The revenue figure surpassed the previously communicated outlook of about 3% CER growth (4% CER core business, excluding discontinued products such as NeuMoDx and Dialunox).
The company expects an adjusted EPS of at least $0.55 (vs. the street view of $0.56) in CER in the quarter, compared to prior guidance of about $0.50 CER.
Qiagen anticipates that the QuantiFERON latent TB test sales will increase by around 15% at CER, driven by the continued global shift from the traditional skin test to this reliable, modern, blood-based alternative.
The QIAstat-Dx syndromic testing system is expected to grow by over 35% CER, fueled by strong demand for respiratory panels and expansion in gastrointestinal and meningitis testing.
Both the QIAcuity digital PCR system and QIAGEN Digital Insights bioinformatics business are projected to show high single-digit CER growth, reflecting strong adoption in research and clinical settings.
However, Sample Technologies sales are expected to decline by 1% CER, reflecting a cautious spending environment among some Life Sciences customers for instruments.
2025 Outlook: The company raised the adjusted EPS outlook to about $2.35 in CER from $2.28 prior (vs. consensus of $2.48) .
The outlook reflects strong sales in the first quarter, expected headwinds from the recently announced U.S. import tariffs and a better-than-expected tax environment.
Meanwhile, Qiagen reiterated the outlook for the adjusted operating income margin to be above 30% for the year.
QIAGEN now expects to achieve its mid-term target for an adjusted operating income margin of at least 31% significantly earlier than planned, well ahead of the original 2028 timeline.
This acceleration reflects stronger-than-expected performance improvements realized throughout 2024 and into 2025.
The company plans to release the first quarter of 2025 results on May 7, 2025 .
Investors can gain exposure to the stock via Global X Genomics & Biotechnology ETF GNOM and First Trust Nasdaq Lux Digital Health Solutions ETF EKG .
Price Action: QGEN shares are up 3.06% at $39.43 premarket at the last check on Monday.
Read Next:
S&P500 Fell 9.1% Last Week And These Large Cap Stocks Were Obliterated (Mar 31-Apr 4)Photo: Shutterstock
QGEN Qiagen NV $39.52 3.29%Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
Reveal Full ScoreEdge Rankings
Momentum 45.18 Growth 36.71 Quality 24.77 Value 25.38Price Trend
Short Medium Long Overview EKG First Trust Nasdaq Lux Digital Health Solutions ETF $14.47 -% GNOM Global X Genomics & Biotechnology ETF $6.86 -5.90% Got Questions? Ask Which biotechnology ETFs could benefit from Qiagen's growth? How will Qiagen's EPS guidance influence investor sentiment? Which genomic companies might see increased competition? How could digital health solutions gain traction post-Qiagen's results? Which life sciences firms may face challenges from declining Sample Technologies sales? What impact could U.S. import tariffs have on Qiagen's competitors? Are there emerging technologies that could disrupt Qiagen's market? Which healthcare sectors could expand due to strong demand for testing? How might global healthcare shifts affect Qiagen's product sales? Who will feel the ripple effects of Qiagen's guidance revisions in the market? Powered By Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Earnings Analyst Ratings Options Dividends IPOs| Date ▲ ▼ | ticker ▲ ▼ | name ▲ ▼ | Actual EPS ▲ ▼ | EPS Surprise ▲ ▼ | Actual Rev ▲ ▼ | Rev Surprise ▲ ▼ |
|---|
Earnings Calendar
Never Miss Important Catalysts
Sort by estimates, projected upside, profit surprises, and more to easily find new stocks to invest in or check up on your portfolio.
Click to JoinPosted In: Earnings Equities Mid Cap News Guidance Movers Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free! Already a member? Sign in